Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a clinical-stage biopharmaceutical company developing non-opioid pain medicines, filed for an initial public offering after reporting positive potentially pivotal data for its lead Nav1.8 inhibitor LTG-001. The company plans to list on the Nasdaq Global Select Market under the ticker "LTGO," although pricing terms have not yet been disclosed.
LTG-001 selectively inhibits Nav1.8, a sodium channel primarily expressed in peripheral pain-sensing neurons. By blocking pain signaling outside the central nervous system, the drug is intended to provide opioid-level analgesia without the risks of addiction or respiratory depression associated with opioid therapy. Latigo is also developing LTG-321, a structurally distinct, next-generation Nav1.8 inhibitor for chronic musculoskeletal pain that has entered a Phase II proof-of-concept trial in knee osteoarthritis, and LTG-418, an earlier Nav1.8 candidate in preclinical development.
Latigo reported that LTG-001 met the primary endpoint in a randomized trial of 343 patients undergoing abdominoplasty, demonstrating statistically significant pain reduction versus placebo and numerically outperforming hydrocodone/acetaminophen. The company believes the study could serve as one of two pivotal trials required for US FDA approval following discussions with the agency.
Latigo's development strategy follows Vertex Pharmaceuticals' January 2025 FDA approval for suzetrigine (Journavx), the first approved Nav1.8 inhibitor, described as establishing a regulatory precedent for the drug class. Beyond Journavx, current standard-of-care options for acute and chronic pain remain dominated by opioids and NSAIDs, which the filing said require tradeoffs between efficacy, safety and addiction risk.